Preliminary statistics from VCBeat identified 26 financing events in China's healthcare sector during the week of December 8-12, 2025 (excluding IPOs and private placements). The week was led by SanegeneBio's over USD 110 million Series B and D3 BIO's USD 108 million Series B.

The round was led by TigerYeah Capital, with participation from several institutions including Optics Valley Industrial Investment, Ennovation Ventures, and Suzhou Leader Ventures. Existing shareholders such as Northern Light Venture Capital and Med-Fine Capital also continued their support in this round. Changhai Capital acted as the exclusive financial advisor.

KYinno is a biotechnology company focused on the research and development of next-generation bispecific and multispecific antibody therapeutics. Building on its proprietary technology platforms — the "common light chain" platform and the "Heavy Chain" nanobody platform — the company is committed to developing globally competitive First-in-Class and Best-in-Class innovative drugs targeting therapeutic areas including oncology and autoimmune diseases.

This round was led by Puhua Capital, with Probe Capital serving as the exclusive financial advisor. The raised capital will be invested in the deep R&D of its core product, the "Trizen Medical LLM and Clinical Application Platform", accelerate cooperative promotion targeting hospitals and physicians, and initiate plans for overseas market expansion.

GentleGen is committed to fundamental technological innovation, continuously breaking through industry bottlenecks. The company has independently developed the world's first fully automated Sanger sequencing production line, an oligonucleotide synthesis automation line, and a high-throughput gene synthesis automation line.

More than betting on a specific device, investors are backing the increasingly evident trend that Synaire aims to address: in modern society, quality sleep is becoming a luxury, yet the nighttime needs of the vast majority of people still lack truly effective solutions.

Founded in 2021, JunFuture is currently focused on building four innovative drug platforms based on fluorocarbon medicine—injectable, ophthalmic, topical, and inhalable—along with establishing a scaled supply chain for the upstream fluorocarbon raw materials. Leveraging the unique inertness and oxygen-carrying properties of fluorocarbons, these medical products have broad potential applications in treating hypoxia, oxidative stress-related injuries and inflammations, as well as in the temporary filling, protection, and lubrication of organs and tissues.

LNK01006 is a next-generation, CNS-penetrant allosteric TYK2 inhibitor that combines potent, selective inhibition of TYK2-mediated cytokine signaling with a pharmacologic profile optimized for central immune modulation.

According to publicly available information, D3S-001 is a next-generation KRAS G12C inhibitor capable of rapid and complete inhibition of the KRAS G12C target. Preclinical studies have demonstrated that D3S-001 exhibits high covalent binding efficiency, achieves complete target inhibition at clinically relevant doses, and possesses central nervous system (CNS) penetration properties.

Under the terms of the agreement, OTR Therapeutics and Zealand Pharma will co-discover and co-develop innovative therapies for multiple targets in metabolic diseases. OTR Therapeutics will leverage its proprietary drug discovery platform to lead and conduct research and preclinical development. Zealand Pharma will assume responsibility for clinical development, regulatory submissions, and commercialization worldwide.

The significant industry interest in YP05002 stems not only from its mechanism as a GLP-1 receptor (GLP-1R) agonist but also from the potential of its "small-molecule + oral" administration route to redefine accessibility and expand application scenarios for GLP-1-based therapies.

The round was led by CDH BAIFU, with continued investment from existing shareholders Xinding Capital and HSG (formerly known as Sequoia Capital China). Index Capital served as the exclusive financial advisor.

Formation Bio has acquired worldwide rights, excluding Greater China, to LNK01006, a next generation central nervous system (CNS)–penetrant highly selective TYK2 inhibitor. The acquisition adds a highly differentiated clinical stage asset to Formation Bio's rapidly expanding portfolio of immunology programs.

Most people know Biocytogen as a leading model animal supplier in China. Around 2021, laboratory mice used in preclinical drug research suddenly became scarce and highly sought after, which brought Biocytogen and its two peers, GemPharmatech and Shanghai Model Organisms Center, into the spotlight. To this day, selling target-humanized model mice remains Biocytogen's primary revenue source.

Founded in 2019, MSTP focuses on breakthroughs in the production processes and industrialization of medical isotopes, striving to become a leading medical isotope supplier in China. The MSTP team brings together experts in nuclear physics, radiochemistry, high-energy accelerators, radiation safety, and related fields.

With 30 years of experience in the pharmaceutical industry, Lee's Pharmaceutical is an integrated, research-driven, and market-oriented biopharmaceutical company. It was listed on the Growth Enterprise Market (GEM) of the HKEX in 2002 and upgraded to the Main Board in 2010, marking simultaneous growth in both capital operations and business development.

Since the third quarter of this year, Fosun Pharma has executed multiple license deals. The company has successively entered into transactions with Sitala and Expedition for FXS6837, intended for the treatment of diseases related to immunomodulation, and XH-S004, intended for the treatment of non-cystic fibrosis bronchiectasis, respectively.

Infinity Neuro primarily focuses on the research, development, production, and commercialization of medical devices in the cerebrovascular field. The company is committed to collaborating closely with neurologists to address unmet clinical needs in neurointervention, with product offerings spanning two core therapeutic areas: hemorrhagic and ischemic stroke.

Levinthal Biotech was established in September 2021 as a technology-driven company specializing in AI algorithm-powered protein design. The company's name, "Levinthal Biotech," pays tribute to the pioneer of molecular biology, Cyrus Levinthal, who proposed the renowned "Levinthal's Paradox": if a protein were to search for its correct structure through random trial and error, the time required would far exceed the age of the universe; in reality, however, proteins can fold within milliseconds.

Jingke Kangyang was co-founded by experts and senior executives with backgrounds from the Chinese Academy of Sciences, Universities of Traditional Chinese Medicine, top-tier hospitals in China, and listed companies.